Sign in to view content

Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model

Andrew A. Moshfeghi, MD, MBA, FASRS

Video
Published 2021

Related

Efficacy and Durability of Brolucizumab in Patients Being Transitioned From Prior Anti-VEGF Therapy
Scott D Walter, MD, MSc, FASRS
Annual Meeting Talks
2021
Phase III Randomized Clinical Trial Comparing SB15 With Reference Aflibercept in Neovascular Age-Related Macular Degeneration 56-Week Results
Min Sagong, MD
Annual Meeting Talks
2023
Intravitreal Aflibercept 8 mg Injection in Patients With Neovascular Age-Related Macular Degeneration: 48-week Results From the Phase 3 PULSAR Trial
Jignesh I Patel, MD FRCOphth
Annual Meeting Talks
2023

Category: Diabetic Retinopathy

See more